Research programme: quinoline compounds - Active BiotechAlternative Names: Inhibition of S100A9 Interactions; ISI; S100A9 Inhibition by Low molecular weight Compounds; SILC
Latest Information Update: 22 Feb 2017
At a glance
- Originator Active Biotech
- Class Quinolines
- Mechanism of Action Advanced glycosylation end-product receptor antagonists; Toll-like receptor 4 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Cancer